Eli Lilly headquarters in Indianapolis. Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs. The Lilly Medicine Foundry ...

Eli Lilly said on Monday it sued three medical ... and misleading consumers about the clinical data used to back them. The Indianapolis-based drugmaker has already sued more than two dozen ...

The newest addition to Eli Lilly and Co.’s manufacturing site ... But the main reasons the Indianapolis-based drugmaker is spending billions of dollars on the massive project boil down to ...

Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading pharmaceutical company that sells Trulicity, Verzenio, and Taltz drugs. The company discovers, develops, and markets human ...

Genetic Leap, a company focused on AI-driven drug discovery, announced Thursday a research collaboration worth up to $409M ...

Shares of Eli Lilly (NYSE: LLY) were sinking 6.3% lower as of 11:11 a.m. ET on Wednesday. The sharp decline came after the big drugmaker announced its third-quarter results before the market opened.

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

But another titan has started to inflate. Ladies and gentlemen, let’s talk about Eli Lilly. There’s something curious about the chart below. Nvidia, the poster child of the AI revolution ...

Drugmaker Eli Lilly signed an agreement with the U.K. government to support early-stage life sciences businesses in the country. As part of the collaboration, which was announced Monday at the U.K ...

Eli Lilly (NYSE:LLY) said that in patients with moderate-to-severe atopic dermatitis who had previously been treated with dupilumab, known by its brand name Dupixent, their Phase 3b study showed ...